华东医药跌2.01%，成交额1.65亿元，主力资金净流出2775.47万元

Core Viewpoint - Huadong Medicine's stock price has shown volatility, with a year-to-date increase of 23.26% but a recent decline in the last five and twenty trading days [1] Financial Performance - For the first half of 2025, Huadong Medicine achieved a revenue of 21.675 billion yuan, representing a year-on-year growth of 3.39% [2] - The net profit attributable to shareholders for the same period was 1.815 billion yuan, reflecting a year-on-year increase of 7.01% [2] Shareholder Information - As of June 30, 2025, the number of shareholders decreased by 7.91% to 69,800, while the average circulating shares per person increased by 8.59% to 25,083 shares [2] - Cumulative cash dividends since the A-share listing amount to 8.873 billion yuan, with 3.771 billion yuan distributed in the last three years [3] Institutional Holdings - As of June 30, 2025, Hong Kong Central Clearing Limited is the third-largest circulating shareholder with 39.8384 million shares, a decrease of 6.2825 million shares from the previous period [3] - The top ten circulating shareholders include various funds, with notable changes in holdings among them, such as an increase in shares held by China Europe Medical Health Mixed A and a decrease by E Fund CSI 300 Medicine ETF [3] Business Overview - Huadong Medicine, established on March 31, 1993, and listed on January 27, 2000, operates primarily in the production and sales of pharmaceutical products, with a revenue composition of 64.45% from commercial activities and 39.69% from manufacturing [1] - The company is involved in various sectors, including vitamins, pharmaceutical e-commerce, vaccine transportation, peptide drugs, and hepatitis treatment [1]